Comparison of Mental Health and Quality of Life in Euthyroid Patients Under Levothyroxine Mono-therapy Based on the Causes of Hypothyroidism

Levothyroxin Monoterapisi Alan Ötiroid Hastalarda Ruh Sağlığı ve Yaşam Kalitesinin Hipotiroidi Nedenlerine Göre Karşılaştırılması

Keywords: Hypothyroidism; thyroxine; mental health; quality of life

Abstract

Objective: A controversy prevails regarding the adequacy of levothyroxine treatment in hypothyroid patients to reduce the risk of psychiatric illness, mood disorders and improve their quality of life. This study evaluated the relationship between different causes of hypothyroidism, mental health, and quality of life in patients treated with levothyroxine. Material and Methods: This cross-sectional study was performed on three groups of hypothyroid patients (Hashimoto thyroiditis, thyroidectomy, radioiodine therapy) treated with levothyroxine for at least six months, with the last thyroid-stimulating hormone within the normal range. After recording the demographic characteristics and thyroid hormone profiles, quality of life [12-item Short-Form Health Survey (SF-12)] and mental health [General Health Questionnaire 28 (GHQ-28)] were evaluated. Results: A total of 109 patients were evaluated in 3 groups as Hashimoto (48 patients), radioiodine therapy (15 patients), and thyroidectomy (46 patients). No significant difference was found between the 3 groups as evaluated by the total score of the SF-12 and GHQ-28 questionnaires. The FT3/FT4 ratio was significantly correlated with five variables related to mental health and quality of life. Conclusion: The study did not find any association between the cause of hypothyroidism and psychological symptoms. However, a possible association between psychological symptoms and thyroid function status is suggested.

Keywords: Hypothyroidism; thyroxine; mental health; quality of life

Anahtar kelimeler: Hipotiroidi; tiroksin; ruh sağlığı; yaşam kalitesi

Özet

Amaç: Hipotiroid hastalarda levothyroxin tedavisinin psikiyatrik hastalık ve duygudurum bozukluğun riskini azaltmadaki ve yaşam kalitesini iyileştirmek için yeterlilik konusundaki bir tartışma söz konusudur. Bu çalışmada, levothyroxin ile tedavi edilen hastalarda hipotiroidizmin farklı nedenleri, ruh sağlığı ve yaşam kalitesi arasında ilklik değerlendirilmiştir. Gereç ve Yöntemler: Bu kesitsel çalışma, en az 6 ay boyunca levothyroxin ile tedavi edilen ve son tiroid uyancı hormon değeri normal aralığı olan 3 grup hipotiroid hasta (Hashimoto tiroiditi, tıroidektomi, radiyoitiot tedavisi) üzerinden yapıldı. Demografik özellikler ve tiroid hormon profileri kaydedildikten sonra yaşam kalitesi [Kisa Form-12 (12-item Short-Form Health Survey “SF-12”)] ve ruh sağlığı [Genel Sağlık Anketi-28 (General Health Questionnaire 28 “GHQ-28”)] değerlendirildi. Bulgular: Hashimoto (48 hasta), radiyoitiot tedavisi (15 hasta) ve tıroidektomi (46 hasta) olmak üzere 3 grupta toplam 109 hasta değerlendirildi. SF-12 ve GHQ-28 anketlerinin toplam puanı ile değerlendirilen 3 grup arasında anlamlı bir fark bulunmadı. FT3/FT4 oranı ise ruh sağlığı ve yaşam kalitesi ile ilişkilili 5 değişkenle analitişte çekilde korel idi. Sonuç: Çalışmada, hipotiroidizmin nedeniyile psikolojik belirti-ler arasında herhangi bir ilklik bulunamamıştır. Bununla birlikte, psikolojik semptomlar ile tiroid fonksiyon durumu arasında bir ilklik söz konusu olabilir.
Introduction

Hypothyroidism is a syndrome caused by thyroid hormone deficiency (1). The annual incidence of primary hypothyroidism in the UK is 3.5 per 1,000 women and 0.6 per 1,000 men (2). In a study in the US, the prevalence of hypothyroidism was estimated to be 4.6% of the total population (3). In a study in Shiraz, Iran, 3.4% of the study population had low thyroid-stimulating hormone (TSH) levels (4). In another study in Iran, the prevalence of hypothyroidism in males and females was found to be 4.8% and 12.8%, respectively (5). Overall, the prevalence of hypothyroidism has been estimated at 5%, with a further estimation of 5% being undiagnosed (1).

Different studies prove that hypothyroidism is associated with anxiety disorders and depression (6). Although anxiety and depression were prevalent among hypothyroid patients, well-treated patients have been found to have the same depressive and cognitive dysfunction as healthy controls (7,8). Hypothyroidism can affect cognitive and mood function and mimic psychiatric disorders in severe cases like major depression (9). Symptoms such as depression, mood changes, and cognitive impairment can disrupt patients’ daily activities and decrease their quality of life (10). The cause of psychiatric disorders in patients with hypothyroidism remains controversial. Factors like alterations in the cerebral circulation increased T3 production, decreased TSH response to thyrotropin-releasing hormone (TRH), changes in neurotransmitter metabolism, and environmental factors can all contribute to these disorders (11).

At present, the standard treatment for hypothyroidism is thyroid hormone replacement with levothyroxine. Some studies report that patients on levothyroxine monotherapy show persistent complaints and nonspecific symptoms, such as weight gain, poor performance of neurocognitive function, and fatigue-related symptoms (12,13). Besides, some other studies indicate that patients after thyroidectomy, who are on levothyroxine monotherapy, often state that their symptoms are not similar to those before surgery (14,15). This evidence has led to the hypothesis that the normal levels of TSH in patients treated with levothyroxine are not necessarily equal to the remission of all symptoms and other variables other than normal TSH levels. However, the relationship between thyroid profiles and patients’ mental health and the role of thyroid hormone replacement therapy remains unclear; further studies are needed to determine its proportions. Therefore, the current study assesses the relation of different causes of hypothyroidism to mental health and quality of life in patients on levothyroxine therapy.

Material and Methods

This study was conducted in a referral hospital clinic (Imam Khomeini Hospital) in Tehran, Iran. The study population comprised all hypothyroid patients referred to this clinic during 2018. The sample size was determined according to 2 mean comparison formulas, considering power 0.8 and alpha 0.05. The mean (standard deviation) of total quality life score in radioiodine therapy and Hashimoto thyroiditis was considered as 30.7 (7.5) and 36.8 (6.2), respectively. The sample size was estimated to be 22 subjects per group.

Inclusion criteria were: at least six months of monotherapy with levothyroxine, TSH within the therapeutic range, age over 20 years, and body mass index between 19-35. Patients with chronic cardiovascular or renal disease, diabetes, hypertension, pregnant women, those on treatment with psychiatric drugs, those taking drugs that influence thyroid hormones status (such as carbamazepine, amiodarone, phenytoin, and lithium), and those with thyroid cancer were excluded. From each patient, 10 cc blood samples were drawn for measuring FT3, FT4, and TSH. TSH was determined using the Padyabteb kit (Padyabteb Inc., Tehran, Iran), while FT3 and FT4 were assessed using the Monobind equipment (Monobind Inc., Lake Forest, CA, USA).

The Persian version of the 12-item Short-Form Health Survey (SF-12) questionnaire, whose validity and reliability had been previously confirmed across several chronic diseases and conditions (16-19), was used to assess the health-related quality of life. The instrument evaluates eight health domain categories. The physical health-related domains include role physical, physical func-
tioning, general health, and body pain. Mental health-related scales include social functioning, role emotional, vitality, and mental health.

Also, the Persian version of the General Health Questionnaire 28 (GHQ-28), whose validity and reliability had been previously confirmed (20), was used to assess mental health. This instrument assesses somatization, anxiety, social dysfunction, and depression. The maximum score for this instrument is 28.

All the collected data were analyzed using the IBM SPSS 20.0 software (IBM Corp, 2009). Continuous and categorical variables have been presented as median [inter quartile range (IQR)] for numerical data and percentages for categorical data. The chi-square test, Kruskal-Wallis, Mann-Whitney U, and Pearson correlation tests were used to compare the data of demographic variables, mental health, and quality of life in the three study groups. Bonferroni correction for comparison between the groups was done in post-hoc analysis after the Kruskal-Wallis test with Mann-Whitney U tests. A p value less than 0.018 was considered significant.

All participants gave informed consent before enrollment, and patient anonymity was preserved. The study was carried out as per the Helsinki Declaration Principles. The study was approved by the Ethics Committee of Tehran University of Medical Sciences (22.07.2018/IR.TUMS.IKHC.REC.1397. 081). In addition, not impose any additional cost to patients.

### Results

One hundred and nine participants were eligible for inclusion in the study. Of these, 17 (15.6%) were men, and 92 (84.4%) were women. Patients were distributed into 3 groups according to the hypothyroidism causes: the Hashimoto group (48 patients), radiiodine therapy group (15 patients), and thyroidectomy group (46 patients). The mean age of patients was 49.72±11.37 years, with a range of 20-73 years. There was no significant difference in the distribution of sex, age, body mass index, and thyroid function tests between groups, except for serum T3, which was lower in the radiiodine therapy group than the Hashimoto group (p=0.003) (Table 1).

Of these, 54.2% of patients in the Hashimoto group, 39.1% patients in the thyroidectomy group, and 40% in the radiiodine therapy group had a good quality of life (score: 32-48), as assessed by a questionnaire (p=0.3). The median (IQR) total scores of the SF-12 questionnaire in the three groups were 37 (9), 34 (15), and 34 (10) in the Hashimoto, radiiodine therapy, and thyroidectomy groups, respectively (p=0.3). No statistically significant difference in the total SF-12 scores and each of the eight SF-12 scales was observed between the 3 groups (p>0.018) (Power=0.67) (Table 2).

Table 1. Baseline characteristics and thyroid function tests in euthyroid patients with different causes for hypothyroidism.

| Group Variable | Radioiodine therapy | Post thyroidectomy | Hashimoto thyroiditis | p value* |
|----------------|---------------------|--------------------|-----------------------|----------|
| Gender (M/F)   | 11/4                | 37/9               | 44/4                  | 0.144    |
| Age, year, median (IQR) | 58 (9)             | 52 (12)            | 46 (15)               | 0.17     |
| BMI, kg/m², median (IQR) | 26.67 (3.54)     | 27.84 (4.64)       | 27.55 (7.08)          | 0.5      |
| Levotyroxine dose, mcg/week, median (IQR) | 700 (200)         | 700 (300)          | 500 (350)             | 0.04     |
| TSH, µIU/mL, median (IQR) | 2.7 (3.6)          | 1.5 (1.75)         | 1.8 (1.9)             | 0.17     |
| FT3, pg/mL, median (IQR) | 2.6 (0.1)          | 2.25 (0.5)         | 2.3 (0.5)             | 0.003    |
| FT4, pg/mL, median (IQR) | 11.3 (2.9)         | 12.4 (2.93)        | 11.9 (3.1)            | 0.25     |
| FT3/FT4, median (IQR) | 0.18 (0.04)        | 0.17 (0.06)        | 0.19 (0.05)           | 0.14     |

*p value based on Kruskal-Wallis test; BMI: Body mass index; TSH: Thyroid-stimulating hormone; IQR: Inter quartile range.
roidectomy was 18 (15), 17 (22), and 17.5 (17), respectively (p=0.8). No statistically significant differences in the total GHQ-28 scores and each of the four domains were observed between the three groups (p>0.05) (Power=0.51) (Table 3).

Table 4 represents the correlations of the total SF-12 scores, each of the eight SF-12 scales, and GHQ-28 scores with thyroid function tests of the participants. Serum levels of FT3, TSH, and FT3/FT4 ratio correlated with social dysfunction score, physical functioning, and vitality, respectively. Other thyroid function tests were not significantly associated with variables related to mental health and quality of life according to the Bonferroni correction in the three study groups.

Discussion

The study compared the quality of life and mental health of three hypothyroid patient groups (radioiodine therapy, thyroidectomy, Hashimoto thyroiditis) after levothyroxine treatment and achieving euthyroid status. No statistically significant differences were observed in patients’ quality of life and mental health between the three groups. Accordingly, these patients’ quality of life and mental health appears to be independent of their cause of hypothyroidism. To the authors’ best knowledge, this is the first study to investigate the quality of life and mental health after euthyroidism with levothyroxine treatment, based on the underlying causes for hypothyroidism.

Table 2. SF-12 scores in euthyroid patients with different causes for hypothyroidism.

| Group         | Variable | Radioiodine therapy (n=15) | Post thyroidectomy (n=46) | Hashimoto thyroiditis (n=48) |
|---------------|----------|-----------------------------|----------------------------|-----------------------------|
| Physical      | PF       | 5 (1)                       | 5 (2)                     | 5 (2)                       |
|               | RP       | 4 (2)                       | 4 (2)                     | 4 (1)                       |
|               | BP       | 4 (1)                       | 4 (1)                     | 4 (2)                       |
|               | GH       | 3 (1)                       | 3 (1)                     | 3 (0)                       |
| Mental        | VT       | 3 (1)                       | 3.5 (1)                   | 3 (2)                       |
|               | SF       | 4 (2)                       | 5 (1)                     | 5 (2)                       |
|               | RE       | 4 (2)                       | 4 (1)                     | 4 (1)                       |
|               | MH       | 8 (3)                       | 8 (2)                     | 9 (3)                       |
| Summary       | PCS      | 15 (5)                      | 14 (5)                    | 15.5 (5)                    |
|               | MCS      | 20 (7)                      | 19 (5)                    | 21 (6)                      |
| Total         |          | 34 (15)                     | 34 (10)                   | 37 (9)                      |

*p value based on Kruskal-Wallis test; Variables as obtained by Median [inter quartile range (IQR)]; PF: Physical functioning; RP: Role physical; BP: Body pain; GH: General health; VT: Vitality; SF: Social functioning; RE: Role emotional; MH: Mental health; PCS: Physical composite scores; MCS: Mental composite scores.

Table 3. GHQ-28 scores in euthyroid patients with different causes for hypothyroidism.

| Group         | Variable     | Radioiodine therapy (n=15) | Post thyroidectomy (n=46) | Hashimoto thyroiditis (n=48) |
|---------------|--------------|-----------------------------|----------------------------|-----------------------------|
|               | Somatization | 6 (9)                       | 5 (6)                     | 5 (3)                       |
|               | Anxiety      | 5 (6)                       | 5 (6)                     | 6 (7)                       |
|               | Social Dysfunction | 7 (2)               | 7 (4)                     | 6 (3)                       |
|               | Depression   | 1 (3)                       | 0 (2)                     | 0 (3)                       |
| Total         |              | 17 (22)                     | 17.5 (17)                 | 18 (15)                     |

*p value based on Kruskal-Wallis test; Variables were presented by Median [inter quartile range (IQR)]; GHQ-28: General Health Questionnaire 28.
Numerous studies have investigated the relationship between thyroid autoimmunity and psychiatric illness and have established conflicting results. Ott et al. reported that in euthyroid females undergoing thyroid surgery for benign thyroid disease, factors like chronic nervousness, chronic fatigue, chronic irritability, and lower quality of life were significantly associated with antithyroid peroxidase (TPO) levels. Ott et al. concluded that in Hashimoto's thyroiditis, higher anti-TPO antibody levels are associated with increased symptom load and decreased quality of life in female euthyroid patients and associated with Hashimoto's symptoms of thyroiditis are not merely due to overt hypothyroidism (21). Three other studies also found this association (22–24). On the other hand, Engum et al., in a large population-based study, found no relation between antithyroid antibodies and depression or anxiety (25). The differences between the present study results and those of the other studies might be due to the small number of patients included in the current study. Besides, most other studies have compared hypothyroid patients with healthy euthyroid people. In contrast, the present study was conducted on three groups of hypothyroid patients (radioiodine therapy, thyroidec- tomy, Hashimoto thyroiditis) treated with levothyroxine.

Another study represented a significant negative correlation between anti-TPO antibody levels and quality of life in patients with Hashimoto thyroiditis on long-standing levothyroxine therapy (26). In this study, patients were euthyroid for at least six months, and the difference in euthyroidism duration between the three groups was not considered.

In the present study, the FT3/FT4 ratio, FT3, and TSH levels were significantly correlated with some variables related to mental health and quality of life in patients with Hashimoto thyroiditis treated with levothyroxine. In this study, patients were euthyroid for at least six months, and the difference in euthyroidism duration between the three groups was not considered.

In the present study, the FT3/FT4 ratio, FT3, and TSH levels were significantly correlated with some variables related to mental health and quality of life (vitality, social dysfunction score, and physical functioning). However, the degree of correlation was weak.

Kritz-Silverstein et al. found that TSH level was unrelated to cognitive function in a community-based sample and was inversely associated with depressed mood in men (27). Contrary to the present study results, Saltevo et al., in a random, population-
based sample of 4,500 subjects, did not find any relation between depressive symptoms and thyroid function tests (28). In the other study by Samuels et al., subjects on levothyroxine therapy with suppressive and replacement doses of levothyroxine did not differ in cognitive function and mood, and there were no correlations between thyroid function tests and health status, mood, and cognition (29).

Future studies to evaluate the factors affecting the quality of life and mental health of hypothyroid patients treated with levothyroxine are warranted. The limitation of this study was the small sample size in each studied group, especially in the radioiodine subgroup, because of the limited cases that are treated with radioiodine in the study center, which could affect the results of this study. Furthermore, assessment before and after initiation of levothyroxine and considering other potential connections, such as smoking with mental health, could have been informative on the treatment effects. Future studies with larger sample sizes, assessment at the initiation of treatment, and longer follow-ups are recommended.

Conclusion
The relationship between thyroid function status and patients’ mental health and the role of thyroid hormone replacement therapy remains unclear and controversial. The study could not find any association between the cause of hypothyroidism and psychological symptoms. However, a possible association between psychological symptoms and thyroid function tests is suggested.

Acknowledgments
We would like to thank the Deputy of research at Tehran University of Medical Sciences, Tehran, Iran.

Source of Finance
During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest
No conflicts of interest between the authors and/or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions
Idea/Concept: Nooshin Shirzad; Design: Mahboobeh Hemmatabadi; Control/Supervision: Fatemeh Esfahanian; Data Collection and/or Processing: Nasrin Asgari-soran; Analysis and/or Interpretation: Mostafa Qorbani; Literature Review: Mahboobeh Hemmatabadi; Writing the Article: Mahboobeh Hemmatabadi; Critical Review: Elham Sharafi; References and Fundings: Nooshin Shirzad; Materials: Nooshin Shirzad.

References
1. Chiovato L, Magri F, Carlé A. Hypothyroidism in context: where we’ve been and where we’re going. Adv Ther. 2019;36:47-58. [Crossref] [Pubmed] [PMC]
2. Vaidya B, Pearce SH. Management of hypothyroidism in adults. BMJ. 2008;337:a801. [Crossref] [Pubmed]
3. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499. [Crossref] [Pubmed]
4. Karimi F, Kalantarhormozi MR, Dabbaghmanesh MH, Ranjbar Omrani G. Thyroid disorders and the prevalence of antithyroid antibodies in Shiraz population. Arch Iran Med. 2014;17:347-351. [Pubmed]
5. Aminorroaya A, Janghorbani M, Amini M, Hovsepian S, Tabatabaei A, Fallah Z. The prevalence of thyroid dysfunction in an iodine-sufficient area in Iran. Arch Iran Med. 2009;12:262-270. [Pubmed]
6. Samuels MH. Psychiatric and cognitive manifestations of hypothyroidism. Curr Opin Endocrinol Diabetes Obes. 2014;21:377-383. [Crossref] [Pubmed] [PMC]
7. Formiga F, Ferrer A, Padros G, Contra A, Corbella X, Pujol R; OCTABAIX Study Group. Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study. Eur J Endocrinol. 2013;170:69-75. [Crossref] [Pubmed]
8. Kramer CK, von Mühlen D, Kritz-Silverstein D, Barrett-Connor E. Treated hypothyroidism, cognitive function, and depressed mood in old age: the Rancho Bernardo Study. Eur J Endocrinol. 2009;161:917-921. [Crossref] [Pubmed]
9. Dayan CM, Panicker V. Hypothyroidism and depression. Eur Thyroid J. 2013;2:168-179. [Crossref] [Pubmed] [PMC]

10. Bianchi GP, Zaccheroni V, Solaroli E, Vescini F, Cerutti R, Zoli M, Marchesini G. Health-related quality of life in patients with thyroid disorders. Qual Life Res. 2004;13:45-54. [Crossref] [Pubmed]

11. Duntas LH, Maillis A. Hypothyroidism and depression: salient aspects of pathogenesis and management. Minerva Endocrinol. 2013;38:365-377. [Pubmed]

12. Louwerens M, Appelhof BC, Verloop H, Medici M, Peeters RP, Visser TJ, Boelen A, Fliers E, Smit JW, Dekkers OM. Fatigue and fatigue-related symptoms in patients treated for different causes of hypothyroidism. Eur J Endocrinol. 2012;167:809-815. [Crossref] [Pubmed]

13. Wartofsky L. Combination L-T3 and L-T4 therapy for hypothyroidism. Curr Opin Endocrinol Diabetes Obes. 2013;20:460-466. [Crossref] [Pubmed]

14. Kaplan MM, Sarve DH, Schneider AB. In search of the impossible dream? Thyroid hormone replacement therapy that treats all symptoms in all hypothyroid patients. J Clin Endocrinol Metab. 2003;88:4543-4550. [Crossref] [Pubmed]

15. Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, StucKey BG, Dhaliwal SS, Chew GT, Bhagat MC, Cussons AJ. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88:4543-4550. [Crossref] [Pubmed]

16. Montazeri A, Vahdaninia M, Mousavi SJ, Omidvari S. The Iranian version of 12-item Short Form Health Survey (SF-12): factor structure, internal consistency and construct validity. BMC Public Health. 2009;9:341. [Crossref] [Pubmed]

17. Huo T, Guo Y, Shenkman E, Muller K. Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study. Health Qual Life Outcomes. 2018;16:34. [Crossref] [Pubmed] [PMC]

18. Bohannon RW, Malajian R, Landes M. Test-retest reliability of short form (SF)-12 component scores of patients with stroke. Int J Rehabil Res. 2004;27:149-150. [Crossref] [Pubmed]

19. Charriylertsak S, Wansom T, Kawichai S, Ruangyutikutkarn C, Kemerer VF, Wu AW. Reliability and validity of Thai versions of the MOS-HIV and SF-12 quality of life questionnaires in people living with HIV/AIDS. Health Qual Life Outcomes. 2011;9:15. [Crossref] [Pubmed] [PMC]

20. Malakouti SK, Fatollahi P, Mirabzadeh A, Zandi T. Reliability, validity and factor structure of the GHQ-28 used among elderly Iranians. Int Psychogeriatr. 2007;19:623-634. [Crossref] [Pubmed]

21. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, Hermann M. Hashimoto’s thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid. 2011;21:161-167. Erratum in: Thyroid. 2011;21(4):467. [Crossref] [Pubmed]

22. Krim S, Keske SO, Köksal F, Haydardeoglu FE, Bozkirli E, Toledano Y. Depression in patients with euthyroid chronic autoimmune thyroiditis. Endocr J. 2012;59:705-708. [Crossref] [Pubmed]

23. Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM, Metcalfe R, Weetman AP. Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab. 1998;83:3194-3197. [Crossref] [Pubmed]

24. Bektas Uysal H, Ayhan M. Autoimmunity affects health-related quality of life in patients with Hashimoto’s thyroiditis. Kaohsiung J Med Sci. 2016; 32:427-433. [Crossref] [Pubmed]

25. Engum A, Bjøro T, Mykletun A, Dahl AA. Thyroid autoimmunity, depression and anxiety; are there any connections? An epidemiological study of a large population. J Psychosom Res. 2005;59:263-268. [Crossref] [Pubmed]

26. Djurovic M, Pereira AM, Smit JWA, Vasovic O, Damjanovic S, Jemcov M, Pavlovic D, Milic D, Pekic S, Stojanovic M, Asanin M, Kriljanac G, Petakov M. Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement. Endocrine. 2018;62:136-143. [Crossref] [Pubmed]

27. Kritz-Silverstein D, Schultz ST, Palinska LA, Wingard DL, Barrett-Connor E. The association of thyroid stimulating hormone levels with cognitive function and depressed mood: the Rancho Bernardo study. J Nutr Health Aging. 2009;13:317-321. [Crossref] [Pubmed] [PMC]

28. Saltevo J, Kautiainen H, Mäntyselkä P, Jula A, Keinänen-Kiukaanniemi S, Korpi-Hyövätö E, Oksa H, Saaristo T, Vanhala M. The relationship between Thyroid Function and Depressive Symptoms—the FIN-D2D Population-Based Study. Clin Med Insights Endocrinol Diabetes. 2015;8:29-33. [Crossref] [Pubmed] [PMC]

29. Samuels MH, Kolobova I, Smeraglio A, Niederhausen M, Janowsky JS, Schuff KG. Effect of thyroid function variations within the laboratory reference range on health status, mood, and cognition in levothyroxine-treated subjects. Thyroid. 2016;26:1173-1184. [Crossref] [Pubmed] [PMC]